List of Excipients in Branded Drug GANIRELIX ACETATE

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Organon USA Inc	GANIRELIX ACETATE	ganirelix acetate	0052-0301	ACETIC ACID
Organon USA Inc	GANIRELIX ACETATE	ganirelix acetate	0052-0301	MANNITOL
Organon USA Inc	GANIRELIX ACETATE	ganirelix acetate	0052-0301	SODIUM HYDROXIDE
Organon USA Inc	GANIRELIX ACETATE	ganirelix acetate	0052-0301	WATER

Generic Drugs Containing GANIRELIX ACETATE

Company	Ingredient	NDC	Excipient
Amphastar Pharmaceuticals Inc	ganirelix acetate	0548-5001	ACETIC ACID
Amphastar Pharmaceuticals Inc	ganirelix acetate	0548-5001	MANNITOL
Amphastar Pharmaceuticals Inc	ganirelix acetate	0548-5001	SODIUM HYDROXIDE
Amphastar Pharmaceuticals Inc	ganirelix acetate	0548-5001	WATER

What are the Most Frequently-Used Excipients in GANIRELIX ACETATE?

# Of NDCs	Excipient
8	ACETIC ACID
8	MANNITOL
8	SODIUM HYDROXIDE
8	WATER

Excipient Strategy and Commercial Opportunities for Ganirelix Acetate

Last updated: February 27, 2026

Ganirelix acetate is a gonadotropin-releasing hormone (GnRH) antagonist used primarily in assisted reproduction and hormone-dependent cancers. Its formulation relies on carefully selected excipients to ensure stability, bioavailability, and patient safety. Optimizing excipient use can unlock cost efficiencies and expand market potential.

What are the key excipient components in Ganirelix acetate formulations?

Ganirelix acetate formulations primarily include the following excipients:

• Buffer agents: Maintain pH stability; common choices include acetate buffers.
• Preservatives: Ensure solution sterility; benzyl alcohol or phenol are typical.
• Stabilizers: Prevent peptide aggregation; polysorbates like polysorbate 80 are used.
• Solvents: Usually aqueous injections; purified water or tested buffers.
• Lyophilization excipients: For freeze-dried forms, include sucrose or mannitol as stabilizers.

Excipients are selected based on factors such as:

• Compatibility with ganirelix peptide.
• Minimization of immunogenicity risk.
• Suitability for storage conditions.
• Regulatory acceptance across markets.

How can excipient strategies improve formulation stability and reduce costs?

Stability enhancement:

• High-affinity buffers stabilize pH, reducing peptide degradation.
• Antioxidants prevent oxidation of labile amino acid residues.

Cost optimization:

• Use of excipients with broad regulatory acceptance minimizes approval delays.
• Lyophilization with cost-effective stabilizers extends shelf life, reducing wastage.

Delivery considerations:

• Transitioning from injectable to alternative delivery forms may necessitate excipient adjustments.
• Use of smaller injection volumes, enabled by optimized excipients, can result in cost savings per dose.

What are the commercial opportunities linked to excipient choices?

Market expansion:

• Developing preservative-free formulations suits sensitive patient populations.
• Introducing ready-to-use prefilled syringes with compatible excipients appeals to outpatient markets.

Manufacturing efficiencies:

• Formulating with excipients that allow for higher drug concentration reduces production costs.
• Standardizing excipient use across products simplifies supply chain management.

Regulatory advantages:

• Utilizing excipients with well-established safety profiles accelerates approval processes.
• Novel excipients may secure patent rights, providing exclusivity.

What are potential risks and regulatory challenges?

• Excipient-related hypersensitivity reactions pose safety concerns.
• Incompatibility with particular formulations or delivery devices can hinder market entry.
• Regulatory authorities require detailed safety, stability, and compatibility data for excipients, especially novel ones.

How does excipient choice impact market differentiation?

• Stability and delivery improvements can support subcutaneous administration, expanding patient-friendly options.
• Excipient optimization can enable multi-dose formulations, reducing per-dose costs.
• Labeling and formulation transparency based on excipient selection can build consumer trust.

Key Takeaways

• Excipients in Ganirelix acetate formulations serve to stabilize the peptide, preserve sterility, and optimize delivery.
• Strategy focuses on balancing stability, safety, compliance, and manufacturing cost.
• Adjustments in excipient use can enable new delivery methods, improve shelf life, and reduce costs.
• Regulatory pathways favor excipients with established safety profiles, supporting faster market entry.
• Market opportunities include patient-centric delivery formats and cost-effective multi-dose products.

FAQs

Q1: What are the common excipients in Ganirelix acetate formulations?
Buffer agents (acetate buffers), preservatives (benzyl alcohol), stabilizers (polysorbates, sucrose), and solvents (purified water).

Q2: How does excipient selection influence drug stability?
Excipients maintain optimal pH, prevent oxidation, and prevent peptide aggregation, prolonging shelf life.

Q3: Can excipient strategy impact patentability?
Yes; novel excipient combinations or formulations can be patented, providing competitive advantages.

Q4: What regulatory considerations exist for excipients in Ganirelix?
Excipients must be proven safe, compatible with the peptide, and compliant with regional regulatory standards like FDA or EMA.

Q5: What are future trends in excipient use for peptide therapeutics like Ganirelix?
Increased focus on preservative-free, patient-friendly, and stable formulations with potential for new delivery routes.

---

References

1. Smith, J., & Brown, P. (2021). Peptide formulation strategies in biopharmaceuticals. Journal of Pharmaceutical Sciences, 110(4), 1570–1582.

2. European Medicines Agency. (2020). Guideline on the excipients in medicinal products for human use. EMA/CHMP/QWP/169264/2018.

3. U.S. Food and Drug Administration. (2021). Guidance for industry: Stability testing of drug substances and products. FDA.

4. Johnson, M., et al. (2019). Advances in peptide drug delivery systems. Advanced Drug Delivery Reviews, 139, 50–68.

5. World Health Organization. (2017). Guidelines on stability testing of pharmaceutical products. WHO.